A Single-Arm, Multicenter, Phase 2 Clinical Study of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate (MRG002) in HER2-Positive Unresectable Locally Advanced or Metastatic Urothelial Carcinoma
MRG002 is a novel HER2-targeted antibody-drug conjugate being investigated in the MRG002-006 trial to evaluate the efficacy and safety in HER2-positive urothelial carcinoma patients. (Source: European Journal of Cancer)
Source: European Journal of Cancer - May 9, 2024 Category: Cancer & Oncology Authors: Wang Qu, Cheng Fu, Weiqing Han, Hong Luo, Jizhong Quan, Lijun Chen, Yong Liao, Changlu Hu, Hailong Hu, Yinong Niu, Danfeng Xu, Minfeng Chen, Jimin Chen, Yongda Liu, Guojun Chen, Zhanxiong Luo, Benkang Shi, Yongkun Sun, Fangjian Zhou, Aiping Zhou Tags: Original Research Source Type: research
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: results from the randomized phase II RE-AKT trial
In this study, we assessed antitumor activity of the AKT inhibitor capivasertib combined with enzalutamide in mCRPC with prior progression on AA and docetaxel. (Source: European Journal of Cancer)
Source: European Journal of Cancer - May 8, 2024 Category: Cancer & Oncology Authors: Pasquale Rescigno, Nuria Porta, Laura Finneran, Ruth Riisnaes, Ines Figueiredo, Suzanne Carreira, Penny Flohr, Susana Miranda, Claudia Bertan, Ana Ferreira, Mateus Crespo, Daniel Nava Rodrigues, Bora Gurel, Jenny Nobes, Simon Crabb, Zafar Malik, Christy R Tags: Clinical Trial Source Type: research
Does patient sex affect the treatment outcome of immune checkpoint inhibitors? A Danish observational melanoma study
The objective of this study was to evaluate whether patient biological sex influences treatment outcomes in patients with metastatic melanoma (MM) undergoing first-line immune checkpoint inhibitor (ICI) therapy. (Source: European Journal of Cancer)
Source: European Journal of Cancer - May 7, 2024 Category: Cancer & Oncology Authors: S øren Kjær Petersen, Christian Rønn Hansen, Eva Ellebaek, Henrik Schmidt, Charlotte Aaquist Haslund, Christina H. Ruhlmann, Lars Bastholt Tags: Original Research Source Type: research
ChatGPT's Gastrointestinal Tumor Board Tango: a limping dance partner?
This study aimed to assess the consistency and replicability of treatment recommendations provided by ChatGPT 3.5 compared to multidisciplinary tumor boards (MTB) gastrointestinal tumors cases. It also aimed to distinguish between general and case-specific responses and investigated the precision of ChatGPT's recommendations in replicating exact treatment plans, particularly regarding chemotherapy regimens and follow-up protocols. (Source: European Journal of Cancer)
Source: European Journal of Cancer - May 7, 2024 Category: Cancer & Oncology Authors: Ughur Aghamaliyev, Javad Karimbayli, Clemens Giessen-Jung, Ilmer Matthias, Kristian Unger, Dorian Andrade, Felix O. Hofmann, Maximilian Weniger, Martin K Angele, C. Benedikt Westphalen, Jens Werner, Bernhard W Renz Tags: Original Research Source Type: research
Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases.
In this study, we sought to assess whether the combination of anti-PD-1 and anti-CTLA-4 leads to better response, progression-free survival and overall survival, compared with anti-PD-1 monotherapy for patients with liver metastases. (Source: European Journal of Cancer)
Source: European Journal of Cancer - May 7, 2024 Category: Cancer & Oncology Authors: Ines Pires da Silva, Isabel Li, Selma Ugurel, Patricio Serra-Bellver, Avanti Andhale, Hannah Burnette, Francisco Aya, Jordan W. Conway, Jorja Braden, Matteo S. Carlino, Alexander M. Menzies, Michael Weichenthal, Peter Mohr, Ralf Gutzmer, Ana M. Arance, Do Tags: Original Research Source Type: research
Trends in incidence, treatment, and relative survival of colorectal cancer in the Netherlands between 2000 and 2021
The epidemiology of colorectal cancer (CRC) has changed rapidly over the years. The aim of this study was to assess the trends in incidence, treatment, and relative survival (RS) of patients diagnosed with CRC in the Netherlands between 2000-2021. (Source: European Journal of Cancer)
Source: European Journal of Cancer - May 7, 2024 Category: Cancer & Oncology Authors: Hidde Swartjes, Femke P.C. Sijtsma, Marloes A.G. Elferink, Felice N. van Erning, Leon M.G. Moons, Henk M.W. Verheul, Maaike Berbee, Pauline A.J. Vissers, Johannes H.W. de Wilt Tags: Original Research Source Type: research
Letter comments on: Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma
Dear Editor, (Source: European Journal of Cancer)
Source: European Journal of Cancer - May 6, 2024 Category: Cancer & Oncology Authors: Sara Elena Rebuzzi, Giuseppe Fornarini, Giuseppe Luigi Banna, Pasquale Rescigno, Sebastiano Buti Tags: Letter to the Editor Source Type: research
Fatal myasthenia gravis (MG) associated with myositis and myocarditis in a patient with pre-existing MG treated by adjuvant nivolumab for a stage III melanoma.
Dear Editor (Source: European Journal of Cancer)
Source: European Journal of Cancer - May 6, 2024 Category: Cancer & Oncology Authors: J. Emile, C. Cauquil, D. Carpentier, E. Routier, Caroline Robert Tags: Letter to the Editor Source Type: research
A fatal case of 5-FU toxicity despite dose adjustment in a patient with a partial DPD deficiency receiving the FLOT regimen
Letter to the editor, (Source: European Journal of Cancer)
Source: European Journal of Cancer - May 6, 2024 Category: Cancer & Oncology Authors: Aziz Zaanan, Nicolas Pallet, C éline Narjoz, Marie-Anne Loriot, Émilie Hafliger Tags: Letter to the Editor Source Type: research
Health-Related Quality Of Life In Trials with High Rates of Early Censoring: Caution Advised
Health-related quality-of-life (HRQoL) data are central to capturing the quality of patients ’ life, while endpoints like overall survival (OS) focus on the quantity of life. When analyzing HRQoL data gathered from patients in a randomized trial, a key consideration is the completion rate - indicating the proportion of patients remaining in the trial and with completed questionnaires. Whe n completion rates are disproportionately low in one treatment arm, one likely explanation is that patients who did not complete questionnaires suffered more from toxicities, negatively impacting their HRQoL. (Source: European Journal of Cancer)
Source: European Journal of Cancer - May 5, 2024 Category: Cancer & Oncology Authors: Timoth ée Olivier, Alyson Haslam, Vinay Prasad Tags: Current Perspective Source Type: research
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review.
T-cell engagers (TCE) are cancer immunotherapies that have recently demonstrated meaningful benefit for patients with hematological malignancies and solid tumors. The anticipated widespread use of T cell engagers poses implementation challenges and highlights the need for guidance to anticipate, mitigate, and manage adverse events. By mobilizing T-cells directly at the contact of tumor cells, TCE mount an obligatory and immediate anti-tumor immune response that could result in diverse reactions and adverse events. (Source: European Journal of Cancer)
Source: European Journal of Cancer - May 3, 2024 Category: Cancer & Oncology Authors: Arthur G éraud, Thomas Hueso, Ariane Laparra, Naike Bige, Kaissa Ouali, Cécile Cauquil, Annabelle Stoclin, François-Xavier Danlos, Antoine Hollebecque, Vincent Ribrag, Anas Gazzah, Vincent Goldschmidt, Capucine Baldini, Steve Suzzoni, Rastislav Bahleda Tags: Review Source Type: research
Editorial Board
(Source: European Journal of Cancer)
Source: European Journal of Cancer - May 1, 2024 Category: Cancer & Oncology Source Type: research
High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma
The development of reliable biomarkers for the prediction of immune checkpoint inhibition (ICI) response in patients with metastatic renal cell carcinoma (mRCC) and urothelial carcinoma (mUC) remains an unresolved challenge. Conventional ICI biomarkers typically focus on tumor-related factors such as PD-L1 expression. However, a comprehensive evaluation of the predictive value of serum electrolyte levels, a so far widely unexplored area, is still pending. (Source: European Journal of Cancer)
Source: European Journal of Cancer - April 28, 2024 Category: Cancer & Oncology Authors: KlumperNiklas Kl ümper, Alexander Cox, Markus Eckstein, Christoph Kuppe, Manuel Ritter, Peter Brossart, Julian Luetkens, HolzelMichael Hölzel, Johannes Stein, Jonas Saal Tags: Original Research Source Type: research
Germline NGS targeted analysis in adult patients with sporadic adrenocortical carcinoma
Adrenocortical carcinoma (ACC) is a rare cancer that arises sporadically or due to hereditary syndromes. Data on germline variants (GVs) in sporadic ACC are limited. Our aim was to characterize GVs of genes potentially related to adrenal diseases in 150 adult patients with sporadic ACC. (Source: European Journal of Cancer)
Source: European Journal of Cancer - April 25, 2024 Category: Cancer & Oncology Authors: Maria Scatolini, Salvatore Grisanti, Pasquale Tomaiuolo, Enrico Grosso, Vittoria Basile, Deborah Cosentini, Soraya Puglisi, Marta Lagan à, Paola Perotti, Laura Saba, Elisa Rossini, Flavia Palermo, Sandra Sigala, Marco Volante, Alfredo Berruti, Massimo Te Tags: Original Research Source Type: research
Real-world treatment patterns and medical costs of prostate cancer patients in Switzerland – a claims data analysis
Prostate cancer (PC) is the most prevalent cancer in men in Switzerland. However, evidence on the real-world health care use of PC patients is scarce. The aim of this study is to describe health care utilization, treatment patterns, and medical costs in PC patients over a period of five years (2014-2018). (Source: European Journal of Cancer)
Source: European Journal of Cancer - April 24, 2024 Category: Cancer & Oncology Authors: Michael Stucki, Stephanie Dosch, Markus Gn ädinger, Sereina M. Graber, Carola A. Huber, Golda Lenzin, Räto T. Strebel, Daniel R. Zwahlen, Aurelius Omlin, Simon Wieser Tags: Original Research Source Type: research
